Tebentafusp-tebu

Cytokine Release Syndrome

• Cytokine Release Syndrome (CRS), which may be serious or lifethreatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated.

Patient Counseling Information

• Kimmtrak

Package Inserts

Tebentafusp-tebu